CDK-002 is under clinical development by Codiak BioSciences and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CDK-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CDK-002 overview

CDK-002 is under development for the treatment of solid tumors including triple-negative breast cancer, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, anaplastic thyroid cancer. The therapeutic candidates comprise of genetically altered exosomes overexpressing PTGFRN and loaded with a cyclic dinucleotide (CDN) small molecule STING agonist which gets delivered to antigen presenting cells (APC). They are developed based on engEx platform. It is administered through intratumor and intrathecal route.

It was also under development for the treatment of lung cancer, muscle invasive bladder cancer, sarcomas, cervical cancer, metastatic hepatocellular carcinoma, glioblastoma multiforme, Leptomeningeal Disease and infectious diseases.

Codiak BioSciences overview

Codiak BioSciences is a clinical-stage biopharmaceutical company that includes development of exosome-based therapeutics. The company pipeline product includes exoVACC, engEx-AAV, oncogene targets, exoASO, exoASO and exoSTING. Its pipeline treats cutaneous T-cell lymphoma (CTCL), solid tumors, myeloid rich cancers, beta coronavirus, gene delivery and hematologic cancers. The company carries out engEx platform. Codiak BioSciences engEx therapeutic areas include oncology, neuro-oncology, neuromuscular disease, infectious disease and rare diseases. It’s exosomes protect and deliver functional macromolecules, including nucleic acids, proteins, lipids and carbohydrates. Codiak BioSciences is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of CDK-002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.